Selected article for: "diffuse consolidation and ground glass"

Author: Matsumura, Kazuki; Toyoda, Yukitoshi; Matsumoto, Shokei; Kawai, Yoshiaki; Mori, Takaaki; Omasa, Kosei; Fukada, Takuya; Yamada, Masaki; Kazamaki, Taku; Furugori, Shintaro; Hiroe, Nao; Senoo, Satomi; Shimizu, Masayuki; Funabiki, Tomohiro; Yamazaki, Motoyasu
Title: Comparison of the Clinical Course of COVID-19 Pneumonia and Acute Respiratory Distress Syndrome in 2 Passengers from the Cruise Ship Diamond Princess in February 2020
  • Cord-id: j9zy7k8s
  • Document date: 2020_8_19
  • ID: j9zy7k8s
    Snippet: Case series Patients: Male, 72-year-old • Male, 70-year-old Final Diagnosis: Acute respiratory distress syndrome (ARDS) • COVID-19 • COVID-19 pneumonia Symptoms: Cough • fever • malaise • nausea • respiratory distress • vomiting Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Infectious Diseases • Radiology OBJECTIVE: Rare disease BACKGROUND: Patients with coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome corona-vi
    Document: Case series Patients: Male, 72-year-old • Male, 70-year-old Final Diagnosis: Acute respiratory distress syndrome (ARDS) • COVID-19 • COVID-19 pneumonia Symptoms: Cough • fever • malaise • nausea • respiratory distress • vomiting Medication: — Clinical Procedure: — Specialty: Critical Care Medicine • Infectious Diseases • Radiology OBJECTIVE: Rare disease BACKGROUND: Patients with coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome corona-virus 2 can rapidly progress to acute respiratory distress syndrome (ARDS). Because clinical diagnosis of ARDS includes several diseases, understanding the characteristics of COVID-19-related ARDS is necessary for precise treatment. We report 2 patients with ARDS due to COVID-19-associated pneumonia. CASE REPORT: Case 1 involved a 72-year-old Japanese man who presented with respiratory distress and fever. Computed tomography (CT) revealed subpleural ground-glass opacities (GGOs) and consolidation. Six days after symptom onset, reverse transcription-polymerase chain reaction (RT-PCR) testing confirmed the diagnosis of COVID-19-associated pneumonia. He was intubated and received veno-venous extracorporeal membrane oxygenation (ECMO) 8 days after symptom onset. Follow-up CT revealed large diffuse areas with a crazy-paving pattern and consolidation, which indicated progression of COVID-19-associated pneumonia. Following treatment with antiviral medications and supportive measures, the patient was weaned off ECMO after 20 days. Case 2 involved a 70-year-old Asian man residing in Canada who presented with cough, malaise, nausea, vomiting, and fever. COVID-19-associated pneumonia was diagnosed based on a positive result from RT-PCR testing. The patient was then transferred to the intensive care unit and intubated 8 days after symptom onset. Follow-up CT showed that while the initial subpleural GGOs had improved, diffuse GGOs appeared, similar to those observed upon diffuse alveolar damage. He was administered systemic steroid therapy for ARDS and extubated after 6 days. CONCLUSIONS: Because the pattern of symptom exacerbation in COVID-19-associated pneumonia cases seems inconsistent, individual treatment management, especially the CT-based treatment strategy, is crucial.

    Search related documents:
    Co phrase search for related documents
    • absorption stage and lung peripheral: 1
    • accurate diagnosis and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • accurate diagnosis and admission day: 1, 2, 3
    • accurate diagnosis and lung change: 1
    • accurate diagnosis and lung peripheral: 1, 2
    • acute hypoxia and admission day: 1
    • acute hypoxia and lopinavir ritonavir: 1
    • acute respiratory syndrome and admission day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and local responsibility: 1
    • acute respiratory syndrome and long maintain: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and low dose radiation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and lung change: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and lung peripheral: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission day and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • admission day and lung peripheral: 1, 2
    • lopinavir ritonavir and low dose radiation: 1